35 results about "Cd4 cell" patented technology

An isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.

Human Immunodeficiency virus causes depletion of CD4 cells. The depletion of CD4 cells results in decrease in immunity of an infected individual. Due to decrease immunity various opportunistic infections occur. These infections are cause for morbidity and mortality in HIV infected individuals. The treatment of HIV these includes antiretroviral drugs. These drugs have their own side effects and immune reconstitution achieved is delayed and slow. Various attempts have been made to improve CD4 count, use of IL-2 is one of them. It is associated with systemic side effects during the period of its administration. The present invention provides method of using mycobacterium w for the management of HIV. According to present invention mycobacterium w when given intradermally is effective in prophylaxis and treatment of AIDS or AIDS related complex (ARC). It is found to improve immunity as well as CD4 count. It is found to eliminate symptoms like fever, diarrhea. The effect is seen even when no antiretrovirals are used.

The present disclosure concerns the treatment of a patient with autoimmune disease, including AIDS, by neutralizing, removing or inhibiting different types of interferons, tumor necrosis factor, HLA class II antigens, IgE, and other pathological factors and / or their receptors, as well as neutralizing, removing or inhibiting autoantibodies, including antibodies to target cells, CD4 cells and DNA. Treatment comprises administration of an autoimmune inhibitor, or extracorporeal exposure of the patient's fluid to an immunosorbent comprising an autoimmune inhibitor, followed by return of the treated fluid to the patient; or it comprises a combined therapy involving extracorporeal immunosorption in conjunction with the administration of an autoimmune inhibitor.

HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and / or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and / or broadly neutralizing antibodies are administered.

The invention provides an oral liquid for controlling HIVs (human immunodeficiency viruses) and a preparation method of the oral liquid. The oral liquid for controlling the HIVs comprises a component I and a component II, wherein the component I is prepared from raw materials in parts by weight as follows: 20-55 parts of fragrant eupatorium herbs, 35-45 parts of trichosanthes roots, 15-18 parts of scorpions, 8-15 parts of centipedes, 22-32 parts of garter snakes, 25-35 parts of white peony roots, 35-45 parts of danshen roots, 15-45 parts of Siberian cocklebur fruits and 500-750 parts of rice wine; the component II is prepared from raw materials in parts by weight as follows: 35-70 parts of daylily roots, 20-55 parts of tortoise plastron and 400-500 parts of rock candy. All the traditional Chinese medicines are combined for use and complement one another, copy propagation of the HIVs in a patient body can be effectively controlled, the number of CD4 cells in the patient body can be increased to be at the normal level, and the body immunity is enhanced; the preparation method of the oral liquid for controlling the HIVs is simple, and the oral liquid is small in toxic and side effects, easy to produce, low in cost and beneficial to energetic popularization.

Provided are an anti-CD4 protein monoclonal antibody, active fragments and uses thereof. The antibody of the present invention can block the binding of the human immunodeficiency virus and human CD4 protein for invasion into cells. The antibody of the present invention can be used for detecting, diagnosing, preventing and treating diseases of which target cells are CD4 cells, especially AIDS caused by the human immunodeficiency virus (HIV). Further provided are corresponding hybridoma cell lines, isolated nucleic acids molecule and oligopeptides, as well as pharmaceutical compositions and kits comprising the monoclonal antibody.